Weather Gauge Advisory LLC decreased its position in AbbVie Inc (NYSE:ABBV) by 14.0% during the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 26,545 shares of the company’s stock after selling 4,326 shares during the quarter. AbbVie makes up 3.1% of Weather Gauge Advisory LLC’s portfolio, making the stock its 7th biggest holding. Weather Gauge Advisory LLC’s holdings in AbbVie were worth $2,606,000 at the end of the most recent quarter.
A number of other large investors have also recently made changes to their positions in the business. Orser Capital Management LLC boosted its holdings in AbbVie by 3,735.5% during the 4th quarter. Orser Capital Management LLC now owns 7,671 shares of the company’s stock valued at $679,000 after acquiring an additional 7,471 shares during the period. Quadrant Capital Group LLC lifted its position in shares of AbbVie by 18.0% during the fourth quarter. Quadrant Capital Group LLC now owns 18,015 shares of the company’s stock worth $1,554,000 after purchasing an additional 2,749 shares during the last quarter. Thrivent Financial for Lutherans boosted its stake in shares of AbbVie by 2.6% during the fourth quarter. Thrivent Financial for Lutherans now owns 84,322 shares of the company’s stock valued at $7,466,000 after purchasing an additional 2,127 shares during the period. Carnegie Capital Asset Management LLC grew its holdings in shares of AbbVie by 60.9% in the fourth quarter. Carnegie Capital Asset Management LLC now owns 13,757 shares of the company’s stock worth $1,218,000 after purchasing an additional 5,205 shares during the last quarter. Finally, Americana Partners LLC purchased a new position in AbbVie in the 4th quarter worth about $32,000. 72.40% of the stock is currently owned by institutional investors and hedge funds.
A number of brokerages have commented on ABBV. Societe Generale downgraded shares of AbbVie from a “buy” rating to a “hold” rating in a research note on Monday, March 23rd. TheStreet raised AbbVie from a “c+” rating to a “b-” rating in a research note on Friday, June 12th. Argus raised AbbVie from a “hold” rating to a “buy” rating and lifted their target price for the company from $91.40 to $115.00 in a research report on Tuesday, June 2nd. Wolfe Research raised AbbVie from a “peer perform” rating to an “outperform” rating in a research report on Tuesday, June 9th. Finally, SVB Leerink raised their price target on AbbVie from $107.00 to $122.00 and gave the company an “outperform” rating in a research note on Monday, May 11th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and fourteen have issued a buy rating to the stock. AbbVie currently has a consensus rating of “Buy” and an average target price of $106.80.
ABBV stock traded up $1.01 during midday trading on Tuesday, reaching $98.87. The stock had a trading volume of 6,752,045 shares, compared to its average volume of 11,111,975. The firm has a fifty day simple moving average of $95.18 and a two-hundred day simple moving average of $87.58. AbbVie Inc has a 52-week low of $62.55 and a 52-week high of $100.69. The stock has a market cap of $142.99 billion, a PE ratio of 17.36, a P/E/G ratio of 2.08 and a beta of 0.86.
AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, May 1st. The company reported $2.42 earnings per share for the quarter, beating analysts’ consensus estimates of $2.25 by $0.17. AbbVie had a negative return on equity of 169.80% and a net margin of 24.77%. The business had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.31 billion. During the same period in the prior year, the company earned $2.14 earnings per share. The company’s revenue was up 10.1% on a year-over-year basis. As a group, research analysts forecast that AbbVie Inc will post 10.5 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be given a dividend of $1.18 per share. This represents a $4.72 dividend on an annualized basis and a yield of 4.77%. The ex-dividend date is Tuesday, July 14th. AbbVie’s dividend payout ratio is presently 52.80%.
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
Featured Story: How do analysts define an oversold condition?
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc (NYSE:ABBV).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.